Form 13-F position report

LIGAND PHARMACEUTICALS INC

Reported by MORGAN STANLEY

LGND CUSIP 53220K504 Manager CIK 0000895421

Reported 206,841 shares, up 6,142 (3.1%) from the prior quarter.

Reported value 1.8%; share count 3.1% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q3 2026
Shares 206,841 Quarter-end amount reported
Reported value $64,611,529 Fair value at quarter end
Consecutive quarters held 54 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 12037000
2022-03-31 16038000
2022-06-30 13223000
2022-09-30 10373000
2022-12-31 12329277
2023-03-31 11407647
2023-06-30 12132014
2023-09-30 11684850
2023-12-31 14226437
2024-03-31 18413672
2024-06-30 16374964
2024-09-30 23722762
2024-12-31 22272469
2025-03-31 25138235
2025-06-30 23009973
2025-09-30 33426885
2025-12-31 36566798
2026-03-31 33387355
2026-06-30 63439444
2026-09-30 64611529

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for LIGAND PHARMACEUTICALS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 206,841 +6,142 (3.1%) < 0.01% $64,611,529 2026-11-13
Q2 2026 Added 200,699 +33,470 (20.0%) < 0.01% $63,439,444 2026-08-13
Q1 2026 Reduced 167,229 -26,173 (-13.5%) < 0.01% $33,387,355 2026-05-15
Q4 2025 Added 193,402 +4,701 (2.5%) < 0.01% $36,566,798 2026-02-13
Q3 2025 Reduced 188,701 -13,708 (-6.8%) < 0.01% $33,426,885 2025-11-14
Q2 2025 Reduced 202,409 -36,683 (-15.3%) < 0.01% $23,009,973 2025-08-15
Q1 2025 Added 239,092 +31,230 (15.0%) < 0.01% $25,138,235 2025-05-15
Q4 2024 Reduced 207,862 -29,151 (-12.3%) < 0.01% $22,272,469 2025-02-14
Q3 2024 Added 237,013 +42,675 (22.0%) < 0.01% $23,722,762 2024-11-14
Q2 2024 Reduced 194,338 -57,559 (-22.9%) < 0.01% $16,374,964 2024-08-14
Q1 2024 Added 251,897 +52,703 (26.5%) < 0.01% $18,413,672 2024-05-15
Q4 2023 Added 199,194 +4,187 (2.1%) < 0.01% $14,226,437 2024-02-13
Q3 2023 Added 195,007 +26,741 (15.9%) < 0.01% $11,684,850 2023-11-15
Q2 2023 Added 168,266 +13,187 (8.5%) < 0.01% $12,132,014 2023-08-14
Q1 2023 Reduced 155,079 -29,491 (-16.0%) < 0.01% $11,407,647 2023-05-15
Q4 2022 Added 184,570 +64,114 (53.2%) < 0.01% $12,329,277 2023-02-14
Q3 2022 Reduced 120,456 -27,755 (-18.7%) < 0.01% $10,373,000 2022-11-14
Q2 2022 Added 148,211 +5,643 (4.0%) < 0.01% $13,223,000 2022-08-15
Q1 2022 Added 142,568 +64,635 (82.9%) < 0.01% $16,038,000 2022-05-13
Q4 2021 Reduced 77,933 -17,629 (-18.4%) < 0.01% $12,037,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

476 managers reported LIGAND PHARMACEUTICALS INC for Q3 2026.

Managers reporting LIGAND PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 3,112,206 +11,210 0.01% $972,159,789 2 qtrs
Invesco Ltd Added 1,503,709 +302,065 0.04% $469,713,581 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 1,112,046 -26,270 0.02% $347,369,809 3 qtrs
FRANKLIN RESOURCES INC Added 912,311 +160,267 0.06% $288,408,877 14 qtrs
JANUS HENDERSON GROUP PLC Reduced 914,350 -95,541 0.12% $285,618,711 1 qtr
VANGUARD CAPITAL MANAGEMENT LLC Reduced 869,478 -1,472 < 0.01% $271,598,843 3 qtrs
STATE STREET CORPORATION Added 834,685 +8,146 < 0.01% $260,730,553 54 qtrs
FMR LLC Reduced 698,920 -63,907 < 0.01% $218,321,723 54 qtrs
CONGRESS ASSET MANAGEMENT CO MA Reduced 658,556 -1,355 1.33% $205,713,138 10 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 586,811 -2,209 < 0.01% $183,332,090 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 13, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
158,874
Shared
0
None
47,967

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.